Bain uses cookies to improve functionality and performance of this site. More information can be found in our Privacy Policy. By continuing to browse this site, you consent to the use of cookies.

We have limited Spanish content available. View Spanish content.

Bloomberg

Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism

Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism

  • octubre 18, 2016
  • min read

Bloomberg

Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism

Large pharmaceutical companies are feeling the pressure from competition with newer pharma companies, particularly in the experimental drug pipelines. These newcomers are gaining footholds in these verticals by building market share in one or two types of tumors or focusing on a technology that can eventually be used more broadly, said Nitin Chaturvedi, a London-based partner with Bain.

“It’s a very credible path to leadership,” Chaturvedi said. “The leadership created through one vertical can be expanded.”